WOCKPHARMA

Wockhardt Share Price

₹1,460.15 -30.05 (-2.02%)

27 Dec, 2024 00:21

SIP TrendupStart SIP in WOCKPHARMA

Start SIP

Performance

  • Low
  • ₹1,450
  • High
  • ₹1,500
  • 52 Week Low
  • ₹403
  • 52 Week High
  • ₹1,537
  • Open Price₹1,496
  • Previous Close₹1,490
  • Volume196,020

Investment Returns

  • Over 1 Month + 12.75%
  • Over 3 Month + 44.56%
  • Over 6 Month + 135.36%
  • Over 1 Year + 255.57%
SIP Lightning

Smart Investing Starts Here Start SIP with Wockhardt for Steady Growth!

Invest Now

Wockhardt Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -82.4
  • PEG Ratio
  • -1.9
  • Market Cap Cr
  • 23,723
  • P/B Ratio
  • 6.5
  • Average True Range
  • 65.48
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 62.8
  • RSI
  • 58.55
  • MFI
  • 53.8

Wockhardt Financials

Wockhardt Technicals

EMA & SMA

Current Price
₹1,460.15
-30.05 (-2.02%)
pointer
  • stock-down_img
  • Bullish Moving Average 14
  • stock-up_img
  • Bearish Moving Average 2
  • 20 Day
  • ₹1,414.41
  • 50 Day
  • ₹1,297.30
  • 100 Day
  • ₹1,151.05
  • 200 Day
  • ₹947.93

Resistance and Support

1470.05 Pivot Speed
  • R3 1,540.10
  • R2 1,520.05
  • R1 1,490.10
  • S1 1,440.10
  • S2 1,420.05
  • S3 1,390.10

What's your outlook on Wockhardt?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wockhardt Ltd. is a global pharmaceutical and biotechnology company specializing in the development, manufacturing, and marketing of medicines, vaccines, and biosimilars. It focuses on key therapeutic areas including anti-infectives, cardiology, and diabetes care.

Wockhardt has an operating revenue of Rs. 2,949.00 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -15% needs improvement, ROE of -13% is poor and needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 69% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 41 which is a POOR score indicating inconsistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wockhardt Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-28 Audited Results
2024-03-26 Others Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.
2024-02-14 Quarterly Results

Wockhardt F&O

Wockhardt Shareholding Pattern

51.99%
2.95%
0%
6.7%
0%
29.02%
9.34%

About Wockhardt

  • NSE Symbol
  • WOCKPHARMA
  • BSE Symbol
  • 532300
  • Managing Director
  • Dr. Murtaza Khorakiwala
  • ISIN
  • INE049B01025

Similar Stocks to Wockhardt

Wockhardt FAQs

Wockhardt share price is ₹1,460 As on 27 December, 2024 | 00:07

The Market Cap of Wockhardt is ₹23723.4 Cr As on 27 December, 2024 | 00:07

The P/E ratio of Wockhardt is -82.4 As on 27 December, 2024 | 00:07

The PB ratio of Wockhardt is 6.5 As on 27 December, 2024 | 00:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23